Iovance lifts 2026 revenue guidance to $410-420 millionSep 29FinancingaldesleukinIovance Biotherapeutics, Inc.
AstraZeneca posts Phase 3 LOGOS, KALOS asthma results; updates Soliris labelJul 2Weekly roundup, 5 itemsAstraZenecaAZD4045
Sign inSign in